ENGNW
MaterialsenGene Holdings Inc - Warrants (31/10/2028)
$2.52+0.26 (+11.50%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ENGNW Today?
No stock-specific AI insight has been generated for ENGNW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.14$4.20
$2.52
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume1K
Avg Volume (10D)—
Shares Outstanding—
ENGNW News
20 articles- enGene Announces Name Change to enGene Therapeutics Inc.Yahoo Finance·Apr 7, 2026
- enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at ConferenceMarketbeat·Mar 15, 2026
- enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays ConferenceMarketbeat·Mar 15, 2026
- enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data UpdateMarketbeat·Mar 15, 2026
- enGene Holdings (ENGN) Is Up 36.9% After Strong Phase 2 Bladder Cancer Gene Therapy ResultsYahoo Finance·Nov 13, 2025
- enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded WarrantsYahoo Finance·Nov 13, 2025
- enGene Announces Proposed Public Offering of Common SharesYahoo Finance·Nov 12, 2025
- enGene’s NMIBC gene therapy touts 63% complete response in pivotal trialClinicaltrialsarena·Nov 11, 2025
- Sector Update: Health Care Stocks Mixed Pre-Bell TuesdayYahoo Finance·Nov 11, 2025
- Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 MonthsYahoo Finance·Nov 11, 2025
- enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND TrialYahoo Finance·Nov 10, 2025
- enGene to Participate in Upcoming Investor ConferencesYahoo Finance·Nov 6, 2025
- enGene Named a BioSpace 2026 Best Places to Work WinnerYahoo Finance·Nov 4, 2025
- enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Yahoo Finance·Oct 1, 2025
- enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical OfficerYahoo Finance·Sep 30, 2025
- enGene Reports Third Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Sep 11, 2025
- enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal CohortYahoo Finance·Sep 3, 2025
- This enGene Holdings Insider Increased Their Holding In The Last YearYahoo Finance·Aug 19, 2025
- enGene Announces Board and Leadership Appointments to Support Commercial ReadinessYahoo Finance·Jul 8, 2025
- FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder CancerYahoo Finance·Jun 25, 2025
All 20 articles loaded
Price Data
Open$2.02
Previous Close$2.26
Day High$2.32
Day Low$1.80
52 Week High$4.20
52 Week Low$0.14
52-Week Range
$0.14$4.20
$2.52
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume1K
Avg Volume (10D)—
Shares Outstanding—
About enGene Holdings Inc - Warrants (31/10/2028)
enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The company is headquartered in Saint-Laurent, Canada.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—